190 related articles for article (PubMed ID: 20549471)
1. Identification of human idiotype-specific T cells in lymphoma and myeloma.
Weng J; Neelapu SS; Woo AF; Kwak LW
Curr Top Microbiol Immunol; 2011; 344():193-210. PubMed ID: 20549471
[TBL] [Abstract][Full Text] [Related]
2. T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma.
Fagerberg J; Yi Q; Gigliotti D; Harmenberg U; Rudén U; Persson B; Osterborg A; Mellstedt H
Int J Cancer; 1999 Mar; 80(5):671-80. PubMed ID: 10048965
[TBL] [Abstract][Full Text] [Related]
3. Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma.
Osterborg A; Henriksson L; Mellstedt H
Acta Oncol; 2000; 39(7):797-800. PubMed ID: 11145435
[TBL] [Abstract][Full Text] [Related]
4. Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.
Weng J; Cha SC; Matsueda S; Alatrash G; Popescu MS; Yi Q; Molldrem JJ; Wang M; Neelapu SS; Kwak LW
Clin Cancer Res; 2011 Sep; 17(18):5945-52. PubMed ID: 21813633
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic lymphoma vaccines: importance of T-cell immunity.
Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
[TBL] [Abstract][Full Text] [Related]
7. The use of a monoclonal anti-idiotype antibody to study the biology of a human B cell lymphoma.
Hatzubai A; Maloney DG; Levy R
J Immunol; 1981 Jun; 126(6):2397-402. PubMed ID: 6785351
[TBL] [Abstract][Full Text] [Related]
8. Determination of idiotype-specific T cells in idiotype-vaccinated mice.
Heyfets A; Haimovich J; Hollander N
Immunol Lett; 2002 Mar; 80(3):207-13. PubMed ID: 11803054
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin.
Moshitzky S; Kukulansky T; Haimovich J; Hollander N
Immunol Cell Biol; 2008; 86(3):261-7. PubMed ID: 18195726
[TBL] [Abstract][Full Text] [Related]
10. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.
Campbell MJ; Carroll W; Kon S; Thielemans K; Rothbard JB; Levy S; Levy R
J Immunol; 1987 Oct; 139(8):2825-33. PubMed ID: 3498771
[TBL] [Abstract][Full Text] [Related]
11. Active idiotype vaccination in multiple myeloma. GM-CSF may be an important adjuvant cytokine.
Mellstedt H; Osterborg A
Pathol Biol (Paris); 1999 Feb; 47(2):211-5. PubMed ID: 10192891
[TBL] [Abstract][Full Text] [Related]
12. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.
Baskar S; Kobrin CB; Kwak LW
J Clin Invest; 2004 May; 113(10):1498-510. PubMed ID: 15146248
[TBL] [Abstract][Full Text] [Related]
13. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
Röllig C; Schmidt C; Bornhäuser M; Ehninger G; Schmitz M; Auffermann-Gretzinger S
J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
[TBL] [Abstract][Full Text] [Related]
15. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
Titzer S; Christensen O; Manzke O; Tesch H; Wolf J; Emmerich B; Carsten C; Diehl V; Bohlen H
Br J Haematol; 2000 Mar; 108(4):805-16. PubMed ID: 10792287
[TBL] [Abstract][Full Text] [Related]
16. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
Kwak LW; Campbell MJ; Czerwinski DK; Hart S; Miller RA; Levy R
N Engl J Med; 1992 Oct; 327(17):1209-15. PubMed ID: 1406793
[TBL] [Abstract][Full Text] [Related]
17. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
[TBL] [Abstract][Full Text] [Related]
18. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
Campbell MJ; Esserman L; Byars NE; Allison AC; Levy R
J Immunol; 1990 Aug; 145(3):1029-36. PubMed ID: 2373859
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of predicted HLA binding of immunoglobulin idiotype sequences indicates T cell-mediated immunosurveillance in follicular lymphoma.
Strothmeyer AM; Papaioannou D; Dühren-von Minden M; Navarrete M; Zirlik K; Heining-Mikesch K; Veelken H
Blood; 2010 Sep; 116(10):1734-6. PubMed ID: 20522710
[TBL] [Abstract][Full Text] [Related]
20. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.
Kwak LW; Taub DD; Duffey PL; Bensinger WI; Bryant EM; Reynolds CW; Longo DL
Lancet; 1995 Apr; 345(8956):1016-20. PubMed ID: 7723498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
